Market Overview

Achillion Achieves 100% Sustained Virologic Response Rate from 8-Week Phase 2 Trial Evaluating Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: News Press Releases

 

Related Articles (ACHN)